Top Markets
Coin of the day
Ortin Laboratories Limited Ortin Laboratories Limited

Ortin Laboratories Limited

ORTINLAB
Classifica tra le azioni #37115
Ortin Laboratories Limited, a pharmaceutical company established in Hyderabad,... Ortin Laboratories Limited, a pharmaceutical company established in Hyderabad, India, in 1986, is engaged in the manufacturing and commercialization of a diverse range of medicines, drugs, and chemical intermediates. The company provides a wide array of pharmaceutical formulations, presented as tablets, capsules, syrups, and dry powders. These products target various therapeutic domains such as metabolic diseases (e.g., anti-diabetics), allergic reactions, infections (including broad-spectrum antibiotics and antifungals like quinolones, penicillins, cephalosporins, macrolides, and antifungals), pain management and fever reduction (analgesics and antipyretics), cardiovascular ailments (anti-anginal and cardiovascular products), digestive system disorders (antacids and anti-ulcerants), neurological and psychiatric conditions (sedatives, tranquilizers, psychiatry products), and nutritional supplementation (like vitamins, calcium, iron, and protein supplements). Specialized offerings also include anti-retroviral, anti-arthritic, anti-helminthic, anti-spasmodic, gynaec, appetite stimulators, and chemotherapeutic preparations. In addition to finished pharmaceuticals, Ortin produces active pharmaceutical ingredient (API) intermediates for applications such as anti-retrovirals, anti-diabetics, pain and fever medications, antibiotics, antifungals, antacids, anti-malarials, and anti-ulcerants. Its manufacturing capabilities also extend to fine chemicals and Grignard/alkali metal compounds. The company offers specialized services covering process development and characterization, analytical research, assay development, and product characterization. It also contributes to diagnostics through the development of rapid flow kits, assays, and reagents. Ortin Laboratories undertakes long-term contracts for the production of intermediates and the creation of novel APIs. Moreover, it actively functions as a merchant exporter of its finished pharmaceutical products.
Prezzo delle azioni
$0.2488447
Ultima sincronizzazione: 2024-10-01
Capitalizzazione di mercato
$2.01M
Variazione (1 giorno)
-1.88%
Variazione (1 anno)
0.00%
Paese
IN
Scambia Ortin Laboratories Limited (ORTINLAB)

Categoria

Rapporto P/E per Ortin Laboratories Limited (ORTINLAB)
Rapporto P/E al August 2026 TTM: -17.26
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Ortin Laboratories Limited, il rapporto P/E attuale (TTM) è -17.26. Alla fine del 2023, il rapporto P/E era -213.31.
Storico del rapporto P/E per Ortin Laboratories Limited da 2008 a 2026
Rapporto P/E alla fine di ogni anno
Anno Rapporto P/E Cambia
2026 (TTM) -17.26 827.97%
2024 -1.86 -99.13%
2023 -213.31 362.83%
2022 -46.09 -272.46%
2021 26.72 -227.08%
2020 -21.03 -211.11%
2019 18.93 -58.98%
2018 46.14 -42.43%
2017 80.15 128.70%
2016 35.05 42.33%
2015 24.62 32.07%
2014 18.64 -8.57%
2013 20.39 17.19%
2012 17.40 16.12%
2011 14.98 137.07%
2010 6.32 -14.89%
2009 7.43 42.83%
2008 5.20 0.00%
Rapporto P/E per aziende simili o concorrenti
Come leggere un P/E ratio?

Il rapporto Prezzo/Utile (P/E) misura la relazione tra il prezzo delle azioni di una società e i suoi utili per azione.
Un P/E basso ma positivo indica un'azienda che genera alti profitti rispetto alla sua valutazione attuale e potrebbe essere sottovalutata. Un'azienda con un P/E negativo elevato (vicino allo 0) segnala forti perdite rispetto alla valutazione.

Le aziende con un P/E superiore a 30 o negativo sono generalmente considerate "azioni di crescita", cioè ci si aspetta che crescano o diventino redditizie.

Le aziende con un P/E positivo inferiore a 10 sono considerate "azioni di valore", ossia già molto redditizie ma con scarse prospettive di crescita.